None listed
Conditions
Interventions
None listed
Sponsors
Hallym University Medical Center-Kangnam
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those who are between 19 and 85 years of age as of the date of obtaining written consent 2) Those diagnosed with erosive gastroesophageal reflux disease (LA grade A-D) on upper gastrointestinal endoscopy within the last 2 weeks as of Visit 2 (enroll date) 3) A person who can understand and follow instructions and participate in the entire clinical trial period 4) Those who voluntarily decide to participate and agree in writing to the clinical trial subject consent form
Exclusion criteria
Exclusion criteria: 1) esophagogastroduodenoscopy shows gastrointestinal bleeding, perforation, esophageal stricture, ulcer stricture, pyloric stricture, esophagogastric varices, long segment Barrett esophagus (LSBE) exceeding 3 cm, dysplastic changes of any grade in the esophagus, those with confirmed malignant tumor 2) Patients diagnosed with eosinophilic esophagitis 3) Patients diagnosed with primary esophageal motility disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), etc. within the past 3 months, or patients suspected of having irritable bowel syndrome 4) Those who have previously undergone surgery to suppress gastric acid secretion or surgery on the stomach or esophagus 5) Patients who have taken concurrent medications (PPI, P-CAB, histamine 2 receptor antagonist, anticholinergic, antacid, mucosal protector, gastrointestinal motility stimulant) within the past 2 weeks as of Visit 2 (enroll date) 6) Patients who must continue to take nonsteroidal anti-inflammatory drugs (NSAIDs) and antithrombotic drugs during the trial period 7) Pregnant or lactating women, or female patients who do not intend to use contraception during the trial period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluating the reduction rate in GERD-HRQL score | — |
Secondary
| Measure | Time frame |
|---|---|
| evaluating the GERD-HRQL score ;evaluating the GERD-Q score ;Evaluate the degree of improvement by evaluating the rate of decrease in GERD-HRQL score after 8 weeks compared to baseline, evaluate change in GERD-HRQL score, and evaluate change in GERDQ score;adverse drug reaction | — |
Countries
Korea, Republic of
Contacts
Public ContactChang Kyo Oh
Hallym University Medical Center-Kangnam
Outcome results
None listed